This episode explores the implications of the latest EAU (European Association of Urology) guidelines and recent surgical trials on prostate cancer treatment, specifically focusing on their relevance to clinical practice in China. Against the backdrop of updated EAU guidelines, the discussion highlights key changes, including a stronger recommendation for transperineal biopsy and the role of MRI in early detection. More significantly, the podcast delves into the TRANSLATE trial, a randomized trial comparing transperineal versus transrectal biopsy, and its surprising findings regarding cancer detection rates. The panelists discuss the NeuroSAFE trial, examining the impact of frozen section nerve sparing on sexual function after radical prostatectomy, while also addressing logistical challenges in implementing this technique. As the discussion pivots to antibiotic usage, the speakers emphasize the importance of antibiotic stewardship and the potential for transperineal biopsy to reduce antibiotic use. The episode concludes with insights on intraoperative margin assessment and emerging technologies, reflecting a trend towards more precise and function-preserving surgical techniques in prostate cancer treatment.
